Get the Stockscreener App
548.81
1.63%
8.78
United Therapeutics Corp stock is traded at $548.81, with a volume of 204.55K.
It is up +1.63% in the last 24 hours and up +9.69% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
See More
Previous Close:
$540.03
Open:
$545.24
24h Volume:
204.55K
Relative Volume:
0.20
Market Cap:
$23.54B
Revenue:
$3.17B
Net Income/Loss:
$1.29B
P/E Ratio:
20.26
EPS:
27.0947
Net Cash Flow:
$1.01B
1W Performance:
+3.01%
1M Performance:
+9.69%
6M Performance:
-4.98%
1Y Performance:
+26.98%
1-Day Range:
$540.00
$551.83
1-Week Range:
$523.95
$555.59
52-Week Range:
$409.07
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
548.81 | 23.54B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
19.64 | 62.75B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.26 | 48.12B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.965 | 43.82B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
78.72 | 32.53B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-26 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-24-26 | Initiated | Goldman | Sell |
| May-07-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
SGIOY or UTHR: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
Liquidia Shares Surge 42.48% After HoursUnited Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
Liquidia Settles United Therapeutics Suits With $380.7M Deal - Law360
Liquidia Just Paid $380 Million to End a Patent War That Crushed the Stock - Money Morning
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH - The Manila Times
Patients with high blood pressure in the lungs will keep access to YUTREPIA as Liquidia settles six lawsuits. - Stock Titan
Martine Rothblatt, United Therapeutics CEO, sells $5.2m in shares - Investing.com
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 12 October - Investing.com Canada
The CEO’s family trust sold 9,500 United Therapeutics (UTHR) shares under a pre-arranged trading plan. - Stock Titan
After exercising options at $117.76, the CEO's trust sold 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics Corporation Presents New Data Across Its Commercial and Development Portfolio At the CHEST 2026 Annual Meeting - marketscreener.com
An inhaled drug still being tested reduced the risk of multiple worsening events for people with lung scarring - Stock Titan
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting - Yahoo Finance
Form 4 United Therapeutics Corporation For: 12 October By Investing.com - Investing.com UK
United Therapeutics CEO Rothblatt sells $5.2m in stock By Investing.com - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.2m in stock - Investing.com
Form 4 United Therapeutics Corporation For: 12 October By Investing.com - Investing.com Nigeria
United Therapeutics CEO Martine Rothblatt sells $5.1m in shares - Investing.com
Form 4 United Therapeutics Corporation For: 10 October By Investing.com - Investing.com Nigeria
Is United Therapeutics Corp (UTHR) Overvalued After 3.1% Rally? - GuruFocus
After exercising 9,500 options, the CEO’s trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
McDermott team recognized by Law.com’s Litigation Daily for patent trial win for United Therapeutics - McDermott Will & Schulte
United Therapeutics chairperson & CEO Martine Rothblatt sells $5.2m in stock - Investing.com
The CEO's family trust exercises options and sells 9,500 United Therapeutics (UTHR) shares under a trading plan. - Stock Titan
LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Family trusts sell 9,500 United Therapeutics (UTHR) shares under a pre-arranged trading plan. - Stock Titan
United Therapeutics Wipes Sandoz $70.6 Million Remodulin Win (1) - Bloomberg Law News
After exercising options at $117.76 per share, United Therapeutics (UTHR) CEO trust sells 9,500 shares. - Stock Titan
CEO trusts sold 9,500 United Therapeutics (UTHR) shares after exercising options at $117.76 each. - Stock Titan
After exercising 9,500 options, a CEO family trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics chairperson & CEO Rothblatt sells $1.06m - Investing.com
United Therapeutics EVP sells $4.69m in shares after option exercise - Investing.com
United Therapeutics CEO Martine Rothblatt disposes of $3.9m in stock - Investing.com
An 8,300-share sale followed an option exercise by United Therapeutics (UTHR) counsel Paul A. Mahon. - Stock Titan
Family trusts sell 1,920 United Therapeutics (UTHR) shares under CEO Rothblatt's trading plan. - Stock Titan
CEO family trusts sell 7,580 shares as United Therapeutics (UTHR) reports a 9,500-option exercise. - Stock Titan
United Therapeutics Jumps 13% After Court Backs Key Patent Claims Against Liquidia - finance.biggo.com
United Therapeutics Corp Stock (UTHR) Moved Up by 7.26% on Oct 1: What Investors Need To Know - tradingkey.com
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback - Zacks Investment Research
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% - Zacks Investment Research
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia - Benzinga
Why is United Therapeutics stock gaining today? - Investing.com
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last? - Zacks Investment Research
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last? - Yahoo! Finance Canada
United Therapeutics Corporation wins Yutrepia PH‑ILD patent ruling - Mugglehead Investment Magazine
United Therapeutics Soars 13% as Court Rules Yutrepia Infringes Its Patent - Yahoo Finance
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 13 '26 |
Sale |
545.52 |
9,500 |
5,182,414 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 12 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 12 '26 |
Sale |
550.70 |
9,500 |
5,231,666 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 09 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 09 '26 |
Sale |
544.94 |
9,500 |
5,176,936 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 08 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 08 '26 |
Sale |
534.31 |
9,500 |
5,075,919 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 07 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 07 '26 |
Sale |
548.95 |
9,500 |
5,215,015 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 06 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
3.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):